1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nanobiotix
  6. News
  7. Summary
    NANO   FR0011341205

NANOBIOTIX

(NANO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Nanobiotix Enrolls First Patient In Late-Stage Trial For Head, Neck Cancer Treatment

01/05/2022 | 11:09pm EDT


© MT Newswires 2022
All news about NANOBIOTIX
05/18CORRECTING AND REPLACING : NANOBIOTIX Provides First Quarter Operational and Financial Upd..
BU
05/18NANOBIOTIX Provides First Quarter Operational and Financial Update
BU
05/18NANOBIOTIX : 1st quarter results
CO
05/17NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
BU
05/11NANOBIOTIX to Participate in Two Upcoming Investor Conferences
BU
05/04NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022
BU
05/02New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022..
BU
04/30NANOBIOTIX : Monthly statement on outstanding equity shares and voting rights
CO
04/11Nanobiotix's Radiotherapy-activated Combination Therapy Shows Improved Anti-tumor Immun..
MT
04/11NANOBOTIX : New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation v..
PU
More news
Analyst Recommendations on NANOBIOTIX
More recommendations
Financials
Sales 2022 1,25 M 1,32 M 1,32 M
Net income 2022 -52,1 M -55,0 M -55,0 M
Net Debt 2022 24,4 M 25,8 M 25,8 M
P/E ratio 2022 -3,43x
Yield 2022 -
Capitalization 179 M 189 M 189 M
EV / Sales 2022 163x
EV / Sales 2023 134x
Nbr of Employees 100
Free-Float 94,5%
Chart NANOBIOTIX
Duration : Period :
Nanobiotix Technical Analysis Chart | NANO | FR0011341205 | MarketScreener
Technical analysis trends NANOBIOTIX
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 5,14 €
Average target price 22,90 €
Spread / Average Target 346%
EPS Revisions
Managers and Directors
Laurent Lévy Chairman-Executive Board & Chief Executive Officer
Bart van Rhijn Chief Financial Officer
Gary M. Phillips Chairman-Supervisory Board
Margaret Galluzzi Vice President-Global & Head-Clinical Operations
Alain Dostie Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
NANOBIOTIX-29.69%189
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567